Literature DB >> 11507221

Latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells.

T S Hyun1, C Subramanian, M A Cotter, R A Thomas, E S Robertson.   

Abstract

The latency-associated nuclear antigen (LANA) is constitutively expressed in cells infected with the Kaposi's sarcoma (KS) herpesvirus (KSHV), also referred to as human herpesvirus 8. KSHV is tightly associated with body cavity-based lymphomas (BCBLs) in immunocompromised patients infected with human immunodeficiency virus (HIV). LANA, encoded by open reading frame 73 of KSHV, is one of a small subset of proteins expressed during latent infection and was shown to be important in tethering the viral episome to host chromosomes. Additionally, it has been shown that LANA can function as a regulator of transcription. However, its role in the progression of disease is still being elucidated. Since KS is one of the most common AIDS-associated cancers in the United States and BCBLs appear predominantly in AIDS patients, we examined whether LANA is able to regulate the HIV type 1 (HIV-1) long terminal repeat (LTR). Using luciferase-based transient transfection assays, we found that LANA was able to transactivate the HIV-1 LTR in the human B-cell line BJAB, human monocytic cell line U937, and the human embryonic kidney fibroblast cell line 293T. Moreover, we observed that the virus-encoded HIV transactivator protein Tat cooperated with LANA in activation of the LTR in a dose-response fashion with increasing amounts of LANA. Surprisingly, LANA alone was sufficient to transactivate the HIV-1 LTR in BJAB cells. In similar assays using a HIV-1 LTR construct with the core enhancer elements deleted; the activity of LANA was diminished but not abolished, indicating a mechanism which involves the cooperation of the core enhancer elements and downstream elements which include Tat. Furthermore, transient transfection of an infectious clone of HIV with LANA demonstrated effects similar to those seen in the reporter assays based on Western blot analysis of HIV Gag polypeptide p24. Interestingly, we also demonstrated that the carboxy terminus of LANA associates with Tat in cells and in vitro. These experiments suggest a role for LANA in activating the HIV-1 LTR through association with cellular molecules targeting the core enhancer elements and Tat and may have important consequences in increasing the levels of HIV in infected individuals and, hence, the disease state.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507221      PMCID: PMC115121          DOI: 10.1128/jvi.75.18.8761-8771.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

Review 1.  A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter.

Authors:  L A Pereira; K Bentley; A Peeters; M J Churchill; N J Deacon
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

2.  p53 inhibition by the LANA protein of KSHV protects against cell death.

Authors:  J Friborg; W Kong; M O Hottiger; G J Nabel
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

3.  Modulation of histone acetyltransferase activity through interaction of epstein-barr nuclear antigen 3C with prothymosin alpha.

Authors:  M A Cotter; E S Robertson
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

4.  Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies.

Authors:  D R Schwam; R L Luciano; S S Mahajan; L Wong; A C Wilson
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene.

Authors:  G M Platt; G R Simpson; S Mittnacht; T F Schulz
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 6.  Classic kaposi sarcoma: epidemiology and risk factors.

Authors:  J Iscovich; P Boffetta; S Franceschi; E Azizi; R Sarid
Journal:  Cancer       Date:  2000-02-01       Impact factor: 6.860

Review 7.  HIV-1-trans-activating (Tat) protein: both a target and a tool in therapeutic approaches.

Authors:  K Watson; R J Edwards
Journal:  Biochem Pharmacol       Date:  1999-11-15       Impact factor: 5.858

8.  The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells.

Authors:  M A Cotter; E S Robertson
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

9.  Seroprevalence of Kaposi's sarcoma-associated herpesvirus in healthy adults in Israel.

Authors:  J Iscovich; A Fischbein; J Fisher-Fischbein; L S Freedman; S M Eng; P Boffetta; A Vudovich; C Glasman; R Goldschmidt; M Livingston; B Heger-Maslansky; P Brennan; P S Moore
Journal:  Anticancer Res       Date:  2000 May-Jun       Impact factor: 2.480

10.  Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.

Authors:  L Arvanitakis; E A Mesri; R G Nador; J W Said; A S Asch; D M Knowles; E Cesarman
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

View more
  34 in total

1.  The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells.

Authors:  Jianhong Hu; Alexander C Garber; Rolf Renne
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 2.  The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Mary E Ballestas; Kenneth M Kaye
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

Review 3.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

4.  Kaposi's sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jkappa, the major downstream effector of the Notch signaling pathway.

Authors:  Ke Lan; Daniel A Kuppers; Erle S Robertson
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function.

Authors:  Huaxin Si; Erle S Robertson
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Identification of a novel cellular transcriptional repressor interacting with the latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus.

Authors:  Hong-Yi Pan; Yan-Jin Zhang; Xin-Ping Wang; Jian-Hong Deng; Fu-Chun Zhou; Shou-Jiang Gao
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 7.  HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.

Authors:  Ryan J Sullivan; Liron Pantanowitz; Corey Casper; Justin Stebbing; Bruce J Dezube
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

8.  Functional dissection of latency-associated nuclear antigen 1 of Kaposi's sarcoma-associated herpesvirus involved in latent DNA replication and transcription of terminal repeats of the viral genome.

Authors:  Chunghun Lim; Hekwang Sohn; Daeyoup Lee; Yousang Gwack; Joonho Choe
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  The gammaherpesvirus 68 latency-associated nuclear antigen homolog is critical for the establishment of splenic latency.

Authors:  Nathaniel J Moorman; David O Willer; Samuel H Speck
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor.

Authors:  Ke Lan; Masanao Murakami; Bharat Bajaj; Rajeev Kaul; Zhiheng He; Runliang Gan; Michael Feldman; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2009-11-07       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.